Drugs / LY011
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04977193 | Nov 2021 → May 2023 | gastric adenocarcinoma | Shanghai Longyao Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT04966143 | Aug 2021 → Aug 2023 | malignant pancreatic neoplasm | Shanghai Longyao Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04966143 ↗ |
| Modality | Cell therapy | “CLDN18.2 Chimeric Antigen Receptor T Cells” NCT04966143 ↗ |
| Target | CLDN18 | “Targeting CLDN 18.2 Chimeric Antigen Receptor T Cells” NCT04977193 ↗ |